Juniper Pharmaceuticals (JNP) Coverage Initiated at Roth Capital

Investment analysts at Roth Capital initiated coverage on shares of Juniper Pharmaceuticals (NASDAQ:JNP) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating and a $12.00 price target on the specialty pharmaceutical company’s stock. Roth Capital’s price objective would indicate a potential upside of 130.77% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. ValuEngine raised Juniper Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. HC Wainwright reaffirmed a “neutral” rating on shares of Juniper Pharmaceuticals in a report on Monday, November 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Juniper Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $23.00.

Juniper Pharmaceuticals (NASDAQ:JNP) traded up $0.30 during midday trading on Tuesday, hitting $5.20. The company’s stock had a trading volume of 262,800 shares, compared to its average volume of 156,350. The company has a market capitalization of $53.14, a PE ratio of 8.81 and a beta of 0.04. Juniper Pharmaceuticals has a 52 week low of $3.65 and a 52 week high of $6.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.00 and a quick ratio of 1.68.

Large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its stake in Juniper Pharmaceuticals by 3.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock valued at $110,000 after purchasing an additional 715 shares during the period. Macquarie Group Ltd. acquired a new position in shares of Juniper Pharmaceuticals in the third quarter worth $129,000. Nationwide Fund Advisors increased its stake in shares of Juniper Pharmaceuticals by 5,500.0% in the second quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock worth $283,000 after acquiring an additional 55,000 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Juniper Pharmaceuticals by 1.9% in the second quarter. Dimensional Fund Advisors LP now owns 72,875 shares of the specialty pharmaceutical company’s stock worth $368,000 after acquiring an additional 1,344 shares during the last quarter. Finally, Algert Global LLC increased its stake in shares of Juniper Pharmaceuticals by 20.4% in the third quarter. Algert Global LLC now owns 144,565 shares of the specialty pharmaceutical company’s stock worth $658,000 after acquiring an additional 24,530 shares during the last quarter. 36.39% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2018/01/04/juniper-pharmaceuticals-jnp-coverage-initiated-at-roth-capital.html.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply